Picture loading failed.

Pre-Made Astegolimab biosimilar, Whole mAb, Anti-IL1RL1/ST2 Antibody: Anti-DER4/FIT-1/IL33R/T1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

The IL-33/ST2 pathway is linked with asthma susceptibility. Inhaled allergens, pollutants, and respiratory viruses, which trigger asthma exacerbations, induce release of IL-33, an epithelial-derived "alarmin." Astegolimab, a human IgG2 mAb, selectively inhibits the IL-33 receptor, ST2.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-033-1mg 1mg 3090
GMP-Bios-ab-033-10mg 10mg Inquiry
GMP-Bios-ab-033-100mg 100mg Inquiry
GMP-Bios-ab-033-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Astegolimab biosimilar, Whole mAb, Anti-IL1RL1/ST2 Antibody: Anti-DER4/FIT-1/IL33R/T1 therapeutic antibody
INN Name Astegolimab
TargetIL1RL1
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesAmgen;Genentech;University of Leicester
Conditions Approvedna
Conditions ActiveAllergic asthma;Atopic dermatitis;Chronic obstructive pulmonary disease
Conditions DiscontinuedAsthma;Rhinosinusitis
Development Techna